Chronic obstructive pulmonary disease: a concise review.

[1]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[2]  I. Yoon,et al.  The association of oxidative stress with central obesity in obstructive sleep apnea , 2012, Sleep and Breathing.

[3]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.

[4]  R. Hancox,et al.  Effects of smoking cannabis on lung function , 2011, Expert review of respiratory medicine.

[5]  G. Lefranc,et al.  Update in chronic obstructive pulmonary disease: role of antioxidant and metabolizing gene polymorphisms , 2011, Experimental lung research.

[6]  D. Sin,et al.  The role of female hormones on lung function in chronic lung diseases , 2011, BMC women's health.

[7]  J. Lammers,et al.  Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. , 2011, Respiratory medicine.

[8]  R. Goeree,et al.  Triple Therapy for the Management of COPD: A Review , 2011, COPD.

[9]  Meilan K. Han,et al.  Update in chronic obstructive pulmonary disease in 2010. , 2011, American journal of respiratory and critical care medicine.

[10]  D. Sin,et al.  Improved patient outcome with smoking cessation: when is it too late? , 2011, International journal of chronic obstructive pulmonary disease.

[11]  Meilan K. Han,et al.  Chronic Azithromycin Decreases The Frequency Of Chronic Obstructive Pulmonary Disease Exacerbations , 2011, ATS 2011.

[12]  T. Seemungal,et al.  Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.

[13]  W. McNicholas,et al.  Obstructive sleep apnea in chronic obstructive pulmonary disease patients , 2011, Current opinion in pulmonary medicine.

[14]  D. Schwartz,et al.  The lung: the natural boundary between nature and nurture. , 2011, Annual review of physiology.

[15]  R. Rodríguez-Roisín,et al.  WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[16]  A. Ernst,et al.  Bronchoscopic lung volume reduction. , 2010, Seminars in thoracic and cardiovascular surgery.

[17]  J. Maurer.  Disease Management Program for Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial , 2011 .

[18]  M. Decramer,et al.  Vitamin D deficiency and chronic obstructive pulmonary disease: a vicious circle. , 2011, Vitamins and hormones.

[19]  E. Wouters,et al.  Treating the systemic effects of chronic obstructive pulmonary disease. , 2011, Proceedings of the American Thoracic Society.

[20]  Hidetoshi Nakamura.  Genetics of COPD. , 2011, Allergology international : official journal of the Japanese Society of Allergology.

[21]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[22]  D. Tashkin.  Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD , 2010, Expert review of respiratory medicine.

[23]  I. Adcock,et al.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[24]  W. Boersma,et al.  Immunomodulatory Effects of Macrolide Antibiotics – Part 1: Biological Mechanisms , 2010, Respiration.

[25]  W. Boersma,et al.  Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy , 2010, Respiration.

[26]  C. Vogelmeier,et al.  Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations , 2010, Respiratory research.

[27]  P. Paré,et al.  Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[28]  I. Adcock,et al.  Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. , 2010, Chest.

[29]  F. Lue,et al.  Theophylline for Chronic Obstructive Pulmonary Disease? ... :Time to Move On , 2010 .

[30]  Tim Lancaster,et al.  Nicotine receptor partial agonists for smoking cessation. , 2010, The Cochrane database of systematic reviews.

[31]  D. Low,et al.  Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae , 2009, BMC Genomics.

[32]  R. Hopkins,et al.  Pharmacological actions of statins: potential utility in COPD , 2009, European Respiratory Review.

[33]  M. Decramer,et al.  Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene , 2009, Thorax.

[34]  D. Postma,et al.  Chronic obstructive pulmonary disease in men and women: myths and reality. , 2009, Proceedings of the American Thoracic Society.

[35]  Gail Gauvreau,et al.  Phosphodiesterase-4 inhibition in COPD , 2009, The Lancet.

[36]  F. Radner,et al.  Budesonide and the risk of pneumonia: a meta-analysis of individual patient data , 2009, The Lancet.

[37]  G. Marks,et al.  Associations between statins and COPD: a systematic review , 2009, BMC pulmonary medicine.

[38]  J. Vestbo,et al.  A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD , 2009, European Respiratory Journal.

[39]  M. Decramer,et al.  Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. , 2009, American journal of respiratory and critical care medicine.

[40]  N. Shahidi,et al.  Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis , 2009, Thorax.

[41]  D. Hui,et al.  Outdoor air pollution: impact on chronic obstructive pulmonary disease patients , 2009, Current opinion in pulmonary medicine.

[42]  K. Shianna,et al.  A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci , 2009, PLoS genetics.

[43]  C. Furberg,et al.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[44]  L. Trupin,et al.  Occupational exposures and the risk of COPD: dusty trades revisited , 2008, Thorax.

[45]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[46]  Liam Ck.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .

[47]  N. Westerhof,et al.  Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. , 2008, Pulmonary pharmacology & therapeutics.

[48]  G. Criner,et al.  Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease. , 2008, Proceedings of the American Thoracic Society.

[49]  B. O'connor,et al.  Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD , 2008, Thorax.

[50]  J. Maurer.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[51]  S. Rennard,et al.  Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. , 2008, Drugs.

[52]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[53]  D. Sin,et al.  Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. , 2007, Proceedings of the American Thoracic Society.

[54]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians , 2007, Annals of Internal Medicine.

[55]  R. Wise,et al.  Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. , 2007, American Journal of Medicine.

[56]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[57]  Richard Casaburi,et al.  Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. , 2007, Chest.

[58]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[59]  I. Rahman,et al.  Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. , 2006, Pharmacology & therapeutics.

[60]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[61]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[62]  R. Scragg,et al.  Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. , 2005, Chest.

[63]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[64]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[65]  S. Guerra.  Overlap of asthma and chronic obstructive pulmonary disease , 2005, Current opinion in pulmonary medicine.

[66]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[67]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[68]  E. Salpeter,et al.  Meta-Analysis: Respiratory Tolerance to Regular 2-Agonist Use in Patients with Asthma , 2004, Annals of Internal Medicine.

[69]  L. Plante.  Obstetricians Wanted: No Mothers Need Apply , 2004, Annals of Internal Medicine.

[70]  J. Tamaoki.  The effects of macrolides on inflammatory cells. , 2004, Chest.

[71]  A. Boyle,et al.  Update on chronic obstructive pulmonary disease. , 2004, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[72]  S. Rennard,et al.  Pathogenesis of COPD , 2005, Seminars in respiratory and critical care medicine.

[73]  N. Anthonisen,et al.  Contemporary management of chronic obstructive pulmonary disease: scientific review. , 2003, JAMA.

[74]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[75]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[76]  S. Sethi.  The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease , 2003, Current infectious disease reports.

[77]  N. Hanania,et al.  The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.

[78]  B. Grant,et al.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.

[79]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[80]  J. Dmochowski,et al.  Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[81]  T. Murphy,et al.  Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. , 2002, The Journal of infectious diseases.

[82]  R. Stockley,et al.  Inflammatory markers in bacterial exacerbations of COPD. , 2002, American Journal of Respiratory and Critical Care Medicine.

[83]  Steven Piantadosi,et al.  Patients at high risk of death after lung-volume-reduction surgery. , 2001, The New England journal of medicine.

[84]  C. Sinderby,et al.  Changes in respiratory effort sensation over time are linked to the frequency content of diaphragm electrical activity. , 2001, American journal of respiratory and critical care medicine.

[85]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[86]  S. Sethi.  Infectious etiology of acute exacerbations of chronic bronchitis. , 2000, Chest.

[87]  P. Dorinsky,et al.  The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. , 1999, Chest.

[88]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[89]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[90]  B. Fischer,et al.  Interactions of oxygen radicals with airway epithelium. , 1994, Environmental health perspectives.

[91]  N. Anthonisen.  [Long-term oxygen therapy]. , 1983, Revue francaise des maladies respiratoires.

[92]  T. De,et al.  Parenteral nutrition before gastrointestinal surgery. , 1982 .

[93]  J. J. Robbins.  What is this thing called love?--or, defining asthma. , 1981, The American review of respiratory disease.

[94]  B. B. Ross,et al.  The effect of smoking cessation and modification on lung function. , 1976, The American review of respiratory disease.

[95]  A. Buist,et al.  Relationship between smoking and the single breath nitrogen washout. , 1976, Scandinavian journal of respiratory diseases. Supplementum.

[96]  D. Sin,et al.  Inhaled Corticosteroids and the Risk of Mortality and Readmission In Elderly Patients with Chronic Obstructive Pulmonary Disease , 2022 .